Infections (all grades) · people with chronic lymphocytic leukaemia
Anti‐leukaemic therapy plus alemtuzumab may leads to higher infections (all grades) compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (low certainty).
1 finding from 1 review
Serious adverse events · people with chronic lymphocytic leukaemia
Anti‐leukaemic therapy plus alemtuzumab showed no clear difference in serious adverse events compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (moderate certainty).
1 finding from 1 review
Overall survival not reported · people with chronic lymphocytic leukaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival ‐ not reported · people with chronic lymphocytic leukaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
OS (at 3 years) · newly diagnosed or relapsed patients with CLL
The intervention leads to lower OS (at 3 years) (high certainty).
1 finding from 1 review
Intervention not reported
TRM · newly diagnosed or relapsed patients with CLL
The intervention showed no clear difference in TRM (low certainty).
1 finding from 1 review
Intervention not reported
PFS (at 3 years) · newly diagnosed or relapsed patients with CLL
The intervention probably leads to lower PFS (at 3 years) (moderate certainty).
1 finding from 1 review
Intervention not reported
TRM · newly diagnosed or relapsed patients with CLL
The intervention showed no clear difference in TRM (moderate certainty).
1 finding from 1 review
Intervention not reported
SAEs ‐ overall analysis · newly diagnosed or relapsed patients with CLL
The intervention showed no clear difference in SAEs ‐ overall analysis (low certainty).
1 finding from 1 review
Intervention not reported
Grade 3/4 AEs ‐ overall analysis · newly diagnosed or relapsed patients with CLL
The intervention probably leads to higher grade 3/4 AEs ‐ overall analysis (moderate certainty).
1 finding from 1 review
Intervention not reported
OS not reported · newly diagnosed or relapsed patients with CLL
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
PFS not reported · newly diagnosed or relapsed patients with CLL
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Intervention not reported
Time to next treatment · newly diagnosed or relapsed patients with CLL
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Intervention not reported
CRR · newly diagnosed or relapsed patients with CLL
The intervention showed no clear difference in CRR (moderate certainty).
1 finding from 1 review
Intervention not reported
All cause mortality ‐ 30 days · Prevention and treatment of infectious complications in patients with acute myelogenous leukemia
The intervention showed no clear difference in all cause mortality ‐ 30 days (low certainty).
1 finding from 1 review
Intervention not reported
Bacteremia · Prevention and treatment of infectious complications in patientswith acute myelogenous leukemia
The intervention showed no clear difference in bacteremia (moderate certainty).
1 finding from 1 review
Intervention not reported
Very wide CI · Prevention and treatment of infectious complications in patientswith acute myelogenous leukemia
1 finding from 1 review
no estimate extracted
1 participants
GRADE not reported
Intervention not reported
Invasive fungal infection · Prevention and treatment of infectious complications in patientswith acute myelogenous leukemia
The intervention showed no clear difference in invasive fungal infection (low certainty).
1 finding from 1 review
Intervention not reported
Episodes of febrile neutropenia · patients with prevention and treatment of infectious complications in patients with acute myelogenous leukemia
The intervention showed no clear difference in episodes of febrile neutropenia (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events requiring discontinuation of CSFs · Prevention and treatment of infectious complications in patients with acute myelogenous leukemia
It is very uncertain whether the intervention changes adverse events requiring discontinuation of CSFs (very low certainty).
1 finding from 1 review